Member Info for Energyshares

We are now 12 months since RNS below could be news soon on progress of this therapy.

29 July 2020
Avacta Group plc
("Avacta" or "the Group" or "the Company")
 
Expansion of Partnership with Daewoong Pharmaceutical to Include COVID-19 Neutralising Affimer Therapy
Collaboration to develop stem cell therapies for COVID-19 and future pandemic diseases
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. (KSX: 069620) and AffyXell Therapeutics, the joint venture established in South Korea by the two companies, to develop stem cell treatments incorporating Avacta's neutralising Affimer therapy for the treatment of seriously ill patients with COVID-19 and to also prepare to rapidly develop similar therapies for future global pandemics.
Respiratory diseases such as COVID-19 can cause serious damage to the lungs as a consequence of over-activation of the patient's immune system, resulting in cytokine release syndrome that can potentially lead to multiple organ failure and death. Stem cell therapies offer a very promising approach to repair the damage to lung tissues in these pulmonary diseases by controlling the immune balance.
AffyXell Therapeutics, the next-generation cell and gene therapy joint venture between Avacta and Daewoong Pharmaceutical, is developing a novel class of mesenchymal stem cell (MSC) treatments that are engineered to also produce Affimer therapies in the patient at the site of action.
The expansion of the agreement between Avacta, Daewoong Pharmaceutical and AffyXell announced today extends the scope of the partnership to include Affimer molecules that target viruses, such as coronaviruses, in order to develop therapies that repair the lung damage caused by COVID-19 whilst also producing neutralising Affimer molecules to prevent the progression of the disease.
AffyXell will engineer mesenchymal stem cells to express SARS-COV-2 neutralising Affimer molecules in order to develop treatments for seriously ill COVID-19 patients, and will also prepare for rapid development of next-generation stem cell therapies for future infectious respiratory disease outbreaks.

Top man
He is a Everton supporter so he is not in Europe.
Last I heard he moved to a Forrest in Essex
:)

ASDA Hero dog meat will be along soon telling he has made a fortune today…,

Come on Ray
We need a moan…..

Remember the interview with Paul Hill.
AS about to talk about other company buy out valuations similar to Avacta before Paul Hill interrupted again and then it was lost.

Therapeutic business could be worth 10x more than diagnostics so AS could be thinking of a split to concentrate on the therapeutics.

Spartacus
Great shout this is what this board should be talking about not a ABDX customer.

Turtle it won’t arrive they don’t accept Groats.

Zoom first link gmcc gave was USA trials
Registered but not yet recruiting.

Great news….

Come on Turtle you have your own payment service:

https://turtlepay.io/

We now have 2 camps ( tribes ) on this board.
The Trolls and the kids in the back of the car “are we there yet”
and the other camp investors who have researched and are taking a long term view to the research they have done.

We hear this a lot “board and management are Scientists, not business people. And certainly not sales people.”

I disagree the management have done a fantastic job in this last 18 months with the amount of deals they have brought to the table confirming the affimer IP is a gold mine.
Social distance working with a lot of staff working from home
AVA6k into trials and Affidx brand launched.

Not business people to me they are business people.

Not Sales people ?
Affidx LFT is the first large product they have had to sell, but no one is giving them any time, moan,moan moan where are the sales.

Listen to investor Q&A
Q8: When can investors expect an update on the Medusa relationship?

Listen to this,we are working really closely with Medusa 19 but we have a confidentiality agreement can’t disclose weekly updates.

But do your research Avacta have gone into a JV with one of the best sales & marketing companies in the UK and probably the best online,they are paying for manufacture ramp up and Home Use validation and we are just sticking our little magic bullets (affimers) into the deal.

Long term hold for me. :)

And ignore that Hero dog meat just posted

States here in RNS clinical study conducted in Europe.
Avacta has 2 sites in UK and none in Europe
So to me this is a independent CV if it wasn’t why didn’t he conduct this study in UK.
Is it the name of the company that performed the study that trolls are asking for…..WHY?
They must be legitimate or he would not of got the CE passed by EU.
Move on..

Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce positive data from the clinical validation of its AffiDX® SARS-CoV-2 antigen lateral flow test. Data from the clinical study conducted in Europe on 98 positive COVID-19 samples demonstrate excellent performance in identifying the SARS-CoV-2 virus across a broad range of viral loads.

Robbo
I bought low and I have also bought at 2.60 into this years ISA, hindsight is a wonderful thing I could of topped up this years ISA now but I didn’t ,I did it in April.
That’s the way the cookie crumbles investing.
But my ISA is long term and I know long term £2.60 was cheap for this IP.
Hold for gold

We are all going over all the same research we have done. All the ducks are lined up that’s why everyone on here has invested.

MM’s know what’s coming hence the SP pressure gathering shares for clients.

AS has not defended SP crash over the last few weeks and you have got to sit back and ask yourself Why ?

UK Home use
EU Home use
AVA6000 trial started
Testing need has exploded
ABDX production
EU production
Major Contracts
Mologic update

One of these babies is going to land soon it could be separate or one Mega RNS and I don’t want to be out.

Relax everyone sit tight ignore the noise from trolls
You will be rewarded.

Noodle
You are a AS basher if your not happy with the way the company is run.
Sell up and go… Arse hole

Radiagreen

A few days ago the was a thread on price of affimers per mg.
I wonder what the cost of supplying a batch of affimers plus a margin would be ?

The (CARD) Mologic want to merge with Affimers to give super sensitive diagnostic tests.

Joe Fitchett is Gates foundation eyes and ears at Mologic.

Paul Davis, Co-Founder and Chief Scientific Officer
Paul has worked in immunology for 45 years and has founded or co-founded eight bioscience businesses since 2002, with Mologic being the most prominent. As Mologic’s chief scientific officer, Paul leads the Centre for Advanced Rapid Diagnostics (CARD), funded by the Bill & Melinda Gates Foundation. Until 2002 he was as a senior scientist at Unilever Research, leading applied immunology, and is one of the inventors of the lateral flow immunoassay.

Joe Fitchett Medical Director
Before joining Mologic, where he oversees our clinical and global health activities, Joe was a program officer at the Bill & Melinda Gates Foundation, where he advanced its bilateral partnerships with EU donors, including the manufacturing capacity of yellow fever vaccine and infectious disease surveillance and control at the Institut Pasteur in Dakar. Previously he was a Frank Knox Fellow in public health and infectious disease epidemiology at Harvard University, focusing on the impact of global policy on vaccines, drugs, and access to health technologies.

Gates foundation have a employee on the board of Mologic ,so lots been going on behind the scenes.
Hope Avacta are involved great for affimer exposure.

Affyxell mentioned in partnerships with India

https://ableindia.in/news/details/1138

This is just for one state in Germany the rest of Germany to follow and 26 other countries in EU block

Not just UK that tests the school children.

2 month contract but ongoing.
Nasal test
Need to detect variants.
Start date of 1/08/2021

Avacta by going for Europe have a very large market to go at.

https://ted.europa.eu/udl?uri=TED:NOTICE:350249-2021:TEXT:EN:HTML&src=0

Translated part below:

Covid-19 antigen rapid tests LEPU or equivalent for pupils in elementary schools.
Students must be able to take the tests independently under supervision. This means that a teacher must be able to safely guide and supervise an entire class at the same time during testing. With the Lepu test, the swab is put into the test booklet immediately after the nasal swab so that the children have both hands free again and can concentrate fully on the next step (open the bottle with buffer solution and drip onto the swab). This prevents the risk of spilling or coming into contact with the buffer liquid. Other tests, such as B. Hotgen or Lyher are out of the question due to the children's limited motor skills.

Covid-19 antigen rapid tests for pupils: inside Tests for pupils: inside secondary schools (from 5th grade).
Self-tests for students to use themselves: from 10 years of age under the supervision of the teacher.
Evaluated by the Bfarm and PEI and approved as a lay test.
Students must be able to take the tests independently under supervision. This means that a teacher must be able to safely guide and supervise an entire class at the same time during testing.
All packaging sizes are permitted.

Covid-19 antigen rapid tests for children in day-care centers
Self-tests to be used by parents on children aged 3 years and over. The tests must be suitable for children aged 3 to 6 years.
Lyher Covid-19 antigen rapid tests (nasal) 5640-S-009/21 are absolutely necessary here because they were selected under scientific supervision for use in children and are currently being evaluated by BIPS. Furthermore, the multilingual information material and the explanatory video are designed for this test.
Evaluated by the Bfarm and PEI and approved as a lay test.

Employees of the state of Bremen and the municipalities of Bremen and Bremerhaven as well as other institutions (see tender documents)
Self-tests for the employees' own use.
The tests must be evaluated by the Bfarm and PEI and approved as a lay test.
The staff must be able to carry out the tests independently.

Well small Chinese takeaway order has set the scene for the weekend.
Unless we get a intra day RNS or one on Monday morning it’s Crybaby nursery again.

Please sell up or shut up it’s called investing.